| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10901a3ef1d1f073204ef5455fa640a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2019-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_608e8c15dfc57cc655368bbc4333afad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6854dd05188282c422bace38c865de87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb7e25d49adcdfab77ba5299f8664a6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb4d28928e95eee49f1b52b62e02e81b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61b101cd8a28a5d7e2acb246adeb9907 |
| publicationDate |
2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113660955-A |
| titleOfInvention |
Immunomodulatory polynucleotide conjugates and methods of using the same |
| abstract |
Provided herein is a conjugate comprising a targeting moiety and an immunomodulatory polynucleotide for modulating natural killer cells or myeloid cells. Also provided herein is a pharmaceutical composition for modulating natural killer cells or myeloid cells comprising a conjugate comprising a targeting moiety and an immunomodulatory polynucleotide, and a pharmaceutically acceptable excipient. Further provided herein are methods of their use in modulating natural killer cells or myeloid cells and treating proliferative diseases. |
| priorityDate |
2018-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |